Introduction: Primary or AL (amyloid Light chain) Amyloidosis is a clonal plasma cell disorder. It is an uncommon disorder and exact incidence is unknown. AL amyloidosis can present with variety of symptoms and signs. There are limited studies about clinical prole, treatment and outcomes of patients with AL Amyloidosis in Indian context. We aim to describe the clinical prole and outcomes of patients with AL amyloidosis in our center. A retrospective descriptive analysis was carried out on patients Materials & Methods: with proven AL amyloidosis, treated from October 2013 to August 2022. Data from 11 patients was compiled and analyzed. The median Results: age at presentation was 54 years. All patients were males (100%). Most common symptoms were pedal oedema in 8 (72%) patients, shortness of breath in 4(36%) patients, Loss of sensations and tingling of upper and lower limbs in 2(18%) patients and lymphadenopathy in 1(9%) patient. Kidney was involved in 7(63%) patients, heart in 3(27%) patients, peripheral nerve in 2(18%) patients and mediastinum in 1(9%) patient. The induction chemotherapy regimens used were Bortezomib-based in 8(72%) patients, Immunomodulator-based in 2(18%) patients. 2(18%) patients underwent Autologous Stem Cell Transplantation (ASCT). Patients who received bortezomib-based treatment had favourable haematological response (62.5%) compared to those who received non-bortezomib-based treatment (9%). Of 11 patients, 3(28%) patients died and 8(72%) patients are alive. This study Conclusion: presents the spectrum of clinical manifestations and outcomes in Indian population. Our study results are in common with the fact that response rates and survival improve with early diagnosis and treatment. Autologous stem cell transplantation should be considered for transplant eligible patients.

Introduction: Diffuse large B cell lymphoma (DLBCL) is the most common lymphoid neoplasm in adults. It accounts for 30% of Non-Hodgkin's lymphomas (NHLs) diagnosed annually [1].The present study aims to evaluate the outcome of the patients who received CHOP(Cyclophosphamide, Adriamycin, Vincristine, Prednisolone) and R(Rituximab)-CHOP treatment and also correlates the different patient characteristics. This was a retrospective analysis carried out on 65 pat Materials & Methods: ients, diagnosed with DLBCL treated from December 2013 to July 2019. A total of 65 cases were studied and their different Results: clinical characteristics are presented in (Table 1). The median age of the study population was 44 years (19–75 years). The male-to-female ratio was 1:0.5. 3year OS (overall survival) was 32% and 43% in CHOP and R-CHOP group and statistically, a signicant difference was seen in both the groups p<0.001. Rituximab based Conclusion: chemoimmunotherapy showed better response rate irrespective of cell of origin.

Takayasu arteritis is a disease of unknown etiology which is a primary systemic vasculitis leading to stenotic and occlusive changes. Takayasu arteritis is a chronic inflammatory disease in progressive pattern which chiefly affects the aorta and its main branches. The diagnosis of the disease is mainly based on the clinical suspicion, history, physical examination and vascular imaging. We present here three cases of takayasu arteritis in pregnancy that were treated at our institute in the last 5 years. 1st case had complications like severe preeclampsia, abruption, temporary loss of vision, and intra uterine death of fetus. In 2nd case there was brain sparing effect of fetus, but other than that she did not have any other complications and neonatal outcome was also good without any neonatal complications. In the 3rd case antenatal and postnatal periods were uneventful and with good neonatal outcome. Pregnancy with takayasu arteritis needs to be timely diagnosed and treated for best maternal and fetal outcome.